This title appears in the Scientific Report :
2018
Please use the identifier:
http://dx.doi.org/10.1007/s10967-018-6238-x in citations.
Please use the identifier: http://hdl.handle.net/2128/20568 in citations.
New developments in the production of theranostic pairs of radionuclides
New developments in the production of theranostic pairs of radionuclides
A brief historical background of the development of the theranostic approach in nuclear medicine is given and seven theranostic pairs of radionuclides, namely 44gSc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 124I/131I, 152Tb/161Tb and 152Tb/149Tb, are considered. The first six pairs consist of a positron...
Saved in:
Personal Name(s): | Qaim, Syed M. (Corresponding author) |
---|---|
Scholten, Bernhard / Neumaier, Bernd | |
Contributing Institute: |
Nuklearchemie; INM-5 |
Published in: | Journal of radioanalytical and nuclear chemistry, 318 (2018) 3, S. 1493 - 1509 |
Imprint: |
Dordrecht [u.a.]
Springer Science + Business Media B.V
2018
|
DOI: |
10.1007/s10967-018-6238-x |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Link: |
Restricted Get full text Restricted Published on 2018-10-19. Available in OpenAccess from 2019-10-19. Published on 2018-10-19. Available in OpenAccess from 2019-10-19. Get full text |
Publikationsportal JuSER |
Please use the identifier: http://hdl.handle.net/2128/20568 in citations.
A brief historical background of the development of the theranostic approach in nuclear medicine is given and seven theranostic pairs of radionuclides, namely 44gSc/47Sc, 64Cu/67Cu, 83Sr/89Sr, 86Y/90Y, 124I/131I, 152Tb/161Tb and 152Tb/149Tb, are considered. The first six pairs consist of a positron and a β−-emitter whereas the seventh pair consists of a positron and an α-particle emitter. The decay properties of all those radionuclides are briefly mentioned and their production methodologies are discussed. The positron emitters 64Cu, 86Y and 124I are commonly produced in sufficient quantities via the (p,n) reaction on the respective highly enriched target isotope. A clinical scale production of the positron emitter 44gSc has been achieved via the generator route as well as via the (p,n) reaction, but further development work is necessary. The positron emitters 83Sr and 152Tb are under development. Among the therapeutic radionuclides, 89Sr, 90Y and 131I are commercially available and 161Tb can also be produced in sufficient quantity at a nuclear reactor. Great efforts are presently underway to produce 47Sc and 67Cu via neutron, photon and charged particle induced reactions. The radionuclide 149Tb is unique because it is an α-particle emitter. The present method of production of 152Tb and 149Tb involves the use of the spallation process in combination with an on-line mass separator. The role of some emerging irradiation facilities in the production of special radionuclides is discussed. |